Intuitive Surgical, Inc. (NASDAQ:ISRG) Position Lifted by Inspire Investing LLC

Inspire Investing LLC increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,718 shares of the medical equipment provider’s stock after purchasing an additional 667 shares during the quarter. Intuitive Surgical makes up 1.6% of Inspire Investing LLC’s holdings, making the stock its 5th largest position. Inspire Investing LLC’s holdings in Intuitive Surgical were worth $16,073,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. Creekmur Asset Management LLC boosted its holdings in Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares during the last quarter. Ridgewood Investments LLC purchased a new stake in Intuitive Surgical during the 2nd quarter valued at about $26,000. Able Wealth Management LLC acquired a new stake in Intuitive Surgical in the 4th quarter valued at about $28,000. Delos Wealth Advisors LLC lifted its stake in Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Finally, LRI Investments LLC acquired a new position in shares of Intuitive Surgical during the 1st quarter worth approximately $30,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $484.78 on Friday. The company’s fifty day moving average is $480.34 and its two-hundred day moving average is $434.94. The firm has a market capitalization of $172.27 billion, a P/E ratio of 83.30, a PEG ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period in the prior year, the business posted $1.18 earnings per share. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Truist Financial lifted their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Evercore ISI raised their target price on Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price objective for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Citigroup raised their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Finally, JPMorgan Chase & Co. upped their target price on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a report on Friday. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $458.35.

Insider Buying and Selling

In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of the business’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $446.60, for a total transaction of $167,921.60. Following the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,458,979.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $446.60, for a total transaction of $167,921.60. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,458,979.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock worth $25,528,753 in the last quarter. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.